Pharmaceutical Executive July 23, 2024
The deals leader at EY Global Life Sciences discusses how the first half of 2024 fared compared to 2023’s strong ending.
After a post-pandemic slump, the life sciences industry saw a strong return for M&A in the latter half of 2023. Many in the industry were curious to see how the first half of 2024 would go, and if the momentum would stay strong. Pharmaceutical Executive spoke with Subin Baral, deals leader at EY Global Life Sciences, about the first half of 2024 from an M&S perspective.
Pharmaceutical Executive: What has defined global M&A in the half of 2024?
Subin Baral: In the Life sciences sector, the momentum from 2023Q4 continued throughout the first half of 2024 as the underlying...
Today's Sponsors
Today's Sponsor